Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer

NCT04878029 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04878029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04878029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination With Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Recruiting
Start date
July 23, 2021
Completion date
December 21, 2028
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating bladder urothelial carcinoma with squamous differentiation, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, unresectable urothelial carcinoma